November 01, 2023
The U.S. Food and Drug Administration was within its right to bar an Alvogen unit from launching its trimmed-down version of Salix's blockbuster drug Xifaxan based on its interpretation of a related court order, a D.C. federal judge said Wednesday.
August 18, 2023
Teva Pharmaceuticals should be allowed to protect its generic exclusivity for its version of a Bausch Health unit's blockbuster irritable bowel syndrome treatment, Xifaxan, by intervening in a competitor's suit, the generic-drug giant has told a D.C. federal court.